GRANITE-001 is a vaccine commercialized by Gritstone Bio, with a leading Phase II program in Metastatic Colorectal Cancer. According to Globaldata, it is involved in 4 clinical trials, of which 3 are ongoing, and 1 was terminated. GlobalData uses proprietary data and analytics to provide a complete picture of GRANITE-001’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for GRANITE-001 is expected to reach an annual total of $163 mn by 2038 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
GRANITE-001 Overview
GRANITE-001 (Zvexneo) is under development for the treatment of pancreatic ductal adenocarcinoma, microsatellite stable colorectal cancer, metastatic non-small cell lung cancer, gastroesophageal adenocarcinoma, bladder cancer such as metastatic urothelial cancer. The drug candidate is a personalized vaccine administered through intramuscular route. It is developed based on Edge neoantigen platform, lipid nanoparticle (LNP) technology, and ZVex platform.
It was also under development for colon cancer.
Gritstone Bio Overview
Gritstone Bio carries out the discovery, development, manufacture and deliver of the cancer and infectious disease immunotherapy candidates. The company product candidate comprises GRT-R910 (samRNA), GRT-C907(ChAd)/-R908 (samRNA), GRT- C909 (ChAd)/- R910(samRNA), GRT-R914 (samRNA), GRT-R912 (samRNA) and GRT-R918 (samRNA). Its infectious diseases pipeline includes coral, a second-generation COVID-19 vaccine program and HIV therapeutic vaccine candidate. Gritstone Bio’s oncology programs comprise granite, an individualized neoantigen-based immunotherapy and slate, to treat non-small cell lung cancer. It also provides Gritstone edge an artificial intelligence and vaccine platforms to predict the tumor-specific neoantigens. The company also carries out the research and development activities and clinical trials. The company operate in Massachusetts and California, the US. Gritstone Bio is headquartered in Emeryville, California, the US.
The company reported revenues of (US Dollars) US$48.2 million for the fiscal year ended December 2021 (FY2021), compared to a revenue of US$4 million in FY2020. The operating loss of the company was US$75.2 million in FY2021, compared to an operating loss of US$106 million in FY2020. The net loss of the company was US$75.1 million in FY2021, compared to a net loss of US$105.3 million in FY2020.
The company reported revenues of US$3 million for the third quarter ended September 2022, a decrease of 44.8% over the previous quarter.
For a complete picture of GRANITE-001’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.
The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.
